Legend Biotech Corporation provided earnings guidance for the six months ended June 30, 2022. For the six months, the company expects to record a loss of approximately USD 196 million to USD 228.9 million and an adjusted loss for the period of approximately USD 144.5 million to USD 168.6 million, in each case, including research and development expenses of approximately USD 135.3 million to USD 157.9 million, which was mainly caused by the continuous investment into its lead product candidate, ciltacabtagene autoleucel (cilta-cel), and other product candidates in Legend Biotech's pipeline.